New hope for deadly lung crisis: experimental combo therapy tested
NCT ID NCT03286556
Summary
This study tested a new combination treatment for patients experiencing a sudden, life-threatening worsening of their lung scarring disease (idiopathic pulmonary fibrosis). Researchers compared an intensive regimen of plasma exchange, the drug rituximab, and immunoglobulin infusions against standard steroid treatment. The goal was to see if reducing harmful antibodies in the blood could improve survival and breathing in these critically ill patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS, ACUTE FATAL FORM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor University Medical Center
Houston, Texas, 77030, United States
-
Dan Dilling
Chicago, Illinois, 60611, United States
-
Temple University Hospital
Philadelphia, Pennsylvania, 19140, United States
-
Thomas Jefferson University Medical Center
Philadelphia, Pennsylvania, 19107, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
-
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Utah Medical Center
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.